Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06529978 · ClinicalTrials.gov registry record · NA
Endocardial Mapping With the CoreMap EP Mapping System
A NA study of Persistent Atrial Fibrillation, sponsored by CoreMap.
- Recruiting
- Registry status
- NA
- Development phase
- 245
- Enrollment target
- 3
- Study locations
NCT06529978: Recruiting NA study of Persistent Atrial Fibrillation, sponsored by CoreMap.
NCT06529978 is a NA study of Persistent Atrial Fibrillation that is actively recruiting participants, run by CoreMap. The registered enrollment target is 245 participants, below the 1,244-participant average among 15 other Persistent Atrial Fibrillation trials with a reported enrollment target (80% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06529978, a NA study of Persistent Atrial Fibrillation, is actively recruiting participants, sponsored by CoreMap.
- RECRUITING
- Registry status
- NA
- Development phase
- 245 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a global, multi-site, prospective, feasibility study.
Primary Outcome
Incidence of study device related serious adverse events within seven (7) days of the study procedure.
Conditions Studied
Interventions
- DEVICE CoreMap EP Mapping System Mapping
- DEVICE CoreMap EP Mapping System Map-Guided Ablation
Study Locations (3)
Florida
- NCH Downtown Baker Hospital - Naples
Vermont
- University of Vermont Medical Center - Burlington
Other
- Na Homolce Hospital - Praha Klanovice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2024-07-25 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT06529978 shows while recruiting
NCT06529978 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, below the 1,244-participant average among 15 other Persistent Atrial Fibrillation trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Persistent Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which CoreMap EP Mapping System Mapping is the first listed.
NCT06529978 reports a single indexed study location in Florida, Vermont, Other.
Frequently Asked Questions
What is clinical trial NCT06529978 about?
NCT06529978 is a clinical study titled "Endocardial Mapping With the CoreMap EP Mapping System". This is a global, multi-site, prospective, feasibility study.
What is the current status of trial NCT06529978?
This trial is currently recruiting. It is a NA study. The enrollment target is 245 participants. The study started on 2024-07-25. Estimated completion is 2026-12-31.
What conditions does trial NCT06529978 study?
This clinical trial studies the following conditions: Persistent Atrial Fibrillation.
What interventions are being tested in trial NCT06529978?
The interventions under investigation include: CoreMap EP Mapping System Mapping (DEVICE), CoreMap EP Mapping System Map-Guided Ablation (DEVICE).
Who is sponsoring clinical trial NCT06529978?
This trial is sponsored by CoreMap, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06529978 being conducted?
This trial has 3 study locations across Florida, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Persistent Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06529978's enrollment target sits among peer trials
245 9th of 15 higher than 7 of 15 other Persistent Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Persistent Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients
RECRUITING · NA
-
ARIADNE Clinical Trial
RECRUITING · NA
-
Medtronic Terminate AF Study
RECRUITING · NA
-
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
RECRUITING · NA
-
Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation
ACTIVE NOT RECRUITING · NA
-
AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI